MedTrace Logo

Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke

NCT01336153 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2011-05-02

No results posted yet for this study

Summary

To investigate the safety and efficacy of MLC601 (NeuroAideTM) as a Traditional Chinese Medicine on motor recovery after ischemic stroke.

Conditions

Interventions

DRUG

MLC601

group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month

DRUG

Placebo

group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    collaborator OTHER

  • Shahid Beheshti University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
72 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-01-31
Completion
2010-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01336153 on ClinicalTrials.gov